Liège, Belgium – 25 February 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), an innovative specialty biopharma company committed to bringing high-value medicines to underserved patients, today announces the appointment of Thomas Jacobsen as Chief Business Development Officer following the retirement of Ed Maloney, who served the company since it was founded.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “On behalf of the entire team, I would like to thank Ed for everything he has done for Hyloris and congratulate him on his achievements over the past eight years. We look forward to working closely with Thomas in further growing our Company as we enter our next stage of development with multiple potential value creating milestones ahead.”
Thomas has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development. He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.
For more information, please contact:
VP Investor Relations and Corporate Communications
M: +32 (0)479 490 603
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Lucy Featherstone
T: +44 20 3709 5700
Hyloris is an innovative specialty biopharma company committed to addressing important underserved medical needs of patients, hospitals, physicians, and payors. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com.